"G(M1) Ganglioside" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.
| Descriptor ID |
D005677
|
| MeSH Number(s) |
D09.400.410.420.025.475.390 D10.390.470.025.475.390 D10.570.877.360.025.475.390
|
| Concept/Terms |
G(M1) Ganglioside- G(M1) Ganglioside
- Monosialosyl Tetraglycosyl Ceramide
- Ceramide, Monosialosyl Tetraglycosyl
- Tetraglycosyl Ceramide, Monosialosyl
|
Below are MeSH descriptors whose meaning is more general than "G(M1) Ganglioside".
Below are MeSH descriptors whose meaning is more specific than "G(M1) Ganglioside".
This graph shows the total number of publications written about "G(M1) Ganglioside" by people in this website by year, and whether "G(M1) Ganglioside" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "G(M1) Ganglioside" by people in Profiles.
-
Schneider JS. GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms. Int J Mol Sci. 2023 May 24; 24(11).
-
Schneider JS, Singh G, Williams CK, Singh V. GM1 ganglioside modifies microglial and neuroinflammatory responses to a-synuclein in the rat AAV-A53T a-synuclein model of Parkinson's disease. Mol Cell Neurosci. 2022 05; 120:103729.
-
Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies a-Synuclein Toxicity and is Neuroprotective in a Rat a-Synuclein Model of Parkinson's Disease. Sci Rep. 2019 06 10; 9(1):8362.
-
Verma M, Schneider JS. siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration. Mol Cell Neurosci. 2019 03; 95:25-30.
-
Schneider JS, Seyfried TN, Choi HS, Kidd SK. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease. PLoS One. 2015; 10(12):e0143351.
-
Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Bra?ic JR, Leiby B, Sendek S, Wong DF. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. J Neurol Sci. 2015 Sep 15; 356(1-2):118-23.
-
Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci. 2013 Jan 15; 324(1-2):140-8.
-
Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson's disease: Results of a five year open study. J Neurol Sci. 2010 May 15; 292(1-2):45-51.
-
Bergstr?m M, Liu S, Kiick KL, Ohlson S. Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: a robust method to evaluate receptor-ligand interactions. Chem Biol Drug Des. 2009 Jan; 73(1):132-41.
-
Giraudo CG, Daniotti JL, Maccioni HJ. Physical and functional association of glycolipid N-acetyl-galactosaminyl and galactosyl transferases in the Golgi apparatus. Proc Natl Acad Sci U S A. 2001 Feb 13; 98(4):1625-30.